ALNY fundamentals
Key facts
Market capitalization34.98 BUSD
Basic EPS (TTM)−2.17USD
Founded2002
Employees (FY)2.23 K
CEOYvonne L. Greenstreet
Websitealnylam.com
About
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002 and is headquartered in Cambridge, MA.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
−34.5%
−26.5%
−18.5%
−10.5%
−2.5%
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
−250.00 M
0.00
250.00 M
500.00 M
750.00 M
Revenue
Net income
Net margin %
Revenue breakdown
Revenue streams and regions a business earns money from
Estimates
Revenue and Earnings forecasts and estimates accuracy
Dividends
Dividend yield, history and sustainability
ALNY does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future
Financial health
Financial position and solvency of the company